In addition, we performed clinicogenomic and immunophenotypic characterization of NSCLC with PD-L1 TPS greater than or equal to 50% to identify features that are unique to NSCLC with a PD-L1 TPS greater than or equal to 90% versus 50% to 89%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.